Biodexa Pharmaceuticals Plc (BDRX)
| Market Cap | 2.39M -40.3% |
| Revenue (ttm) | n/a |
| Net Income | -8.59M |
| EPS | -78.31 |
| Shares Out | 648.31K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,970 |
| Open | 3.840 |
| Previous Close | 4.250 |
| Day's Range | 3.650 - 4.100 |
| 52-Week Range | 2.860 - 96.500 |
| Beta | 1.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 12, 2025 |
About BDRX
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse m... [Read more]
News
Biodexa Pharmaceuticals PLC-ADR trading halted, news pending
19:50 EDT Biodexa Pharmaceuticals (BDRX) PLC-ADR trading halted, news pending
Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene
Biodexa Pharmaceuticals (BDRX) announced that it has partnered with Syngene for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biophar...
Biodexa, Tanner Pharma launch global early access program for FAP patients
Tanner Pharma Group and Biodexa Pharmaceuticals (BDRX) have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis, FAP, through an Early A...
Preliminary Results for the Year Ended 31 December 2025
March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals ...
Biodexa Pharmaceuticals management to meet with Maxim
Meeting to be held on March 23-27 hosted by Maxim.
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical sta...
Biodexa Pharmaceuticals announces one-for-five reverse ADR split
Biodexa Pharmaceuticals (BDRX) announced a ratio change on its American Depositary Receipts from one ADR representing 100,000 ordinary shares, to the new ratio of one ADR representing 500,000 ordinary...
ADR Ratio Change
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of...
Biodexa Pharmaceuticals supports Life’s a Polyp Foundation
Biodexa Pharmaceuticals (BDRX) is pleased to recognise Life’s a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization’s vital work empow...
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
March 9, 2026 Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a cli...
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 20...
Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical
Biodexa Pharmaceuticals (BDRX) announced the closing of an exclusive license with Otsuka Pharmaceutical for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointes...
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models ...
Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary
Biodexa Pharmaceuticals (BDRX) announced the promotion of Fiona Sharp to CFO and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Sharp…
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq:...
Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering
Biodexa Pharmaceuticals (BDRX) announced the pricing of a best efforts public offering of an aggregate of 157,000 units, with each unit consisting of one American depositary share, and two Series…
Biodexa Announces Pricing of $10 Million Public Offering
December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developi...
Biodexa Pharmaceuticals PLC-ADR trading resumes
09:36 EST Biodexa Pharmaceuticals (BDRX) PLC-ADR trading resumes
Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause
09:31 EST Biodexa Pharmaceuticals (BDRX) PLC-ADR trading halted, volatility trading pause
Biodexa announces enrollment of first European patients in Phase 3 Serenta trial
Biodexa Pharmaceuticals (BDRX) announced the enrolment of the first three patients by the University of Bonn, Germany into its pivotal Phase 3 Serenta trial of eRapa in patients with familial…
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical s...
Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial
Biodexa Pharmaceuticals (BDRX) announced that the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polypos...
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany ...
Biodexa Pharmaceuticals files to sell 3.38M units
17:03 EST Biodexa Pharmaceuticals (BDRX) files to sell 3.38M units